Delcath Systems, Inc. (NASDAQ: DCTH) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | 0.01 | Insider Own | - | Shs Outstand | 34.52M | Perf Week | 1.26% |
| Market Cap | 556.14M | Forward P/E | - | EPS next Y | -0.06 | Insider Trans | 0.00% | Shs Float | 28.60M | Perf Month | -6.06% |
| Enterprise Value | 511.09M | PEG | - | EPS next Q | -0.10 | Inst Own | - | Short Float | 7.84% | Perf Quarter | 37.81% |
| Income | 500.53K | P/S | 5.83 | EPS this Y | -1900.00% | Inst Trans | - | Short Ratio | 3.97 | Perf Half Y | 72.48% |
| Sales | 95.42M | P/B | 4.77 | EPS next Y | 67.20% | ROA | 0.39% | Short Interest | 2.24M | Perf YTD | 59.50% |
| Book/sh | - | P/C | 29.52 | EPS next 5Y | - | ROE | 0.46% | 52W High | 17.42 -7.52% | Perf Year | 43.84% |
| Cash/sh | - | P/FCF | 31.77 | EPS past 3/5Y | - | ROIC | -0.60% | 52W Low | 8.12 98.40% | Perf 3Y | 255.63% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 204.86% 111.68% | Gross Margin | 87.05% | Volatility | 2.77% 2.51% | Perf 5Y | 55.65% |
| Dividend TTM | - | EV/Sales | 5.36 | EPS Y/Y TTM | 108.40% | Oper. Margin | -1.90% | ATR (14) | 0.49 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 8.95 | Sales Y/Y TTM | 159.46% | Profit Margin | 0.56% | RSI (14) | 52.49 | Recom | 2.36 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.83 | EPS Q/Q | 0.00% | SMA20 | -1.56% | Beta | 0.59 | Target Price | 24.50 |
| Payout | 0.00% | Debt/Eq | 0.02 | Sales Q/Q | 20.83% | SMA50 | 7.49% | Rel Volume | 1.36 | Prev Close | 16.25 |
| Employees | 156 | LT Debt/Eq | 0.01 | Earnings | Nov 03 | SMA200 | 39.14% | Avg Volume | 515.95K | Price | 16.11 |
| IPO Date | May 03, 2018 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 178.53% 10.97% | Net Debt/EBITDA | -26.58 | Volume | 703,094 | Change | -0.86% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-07-26 | Reiterated | HC Wainwright & Co. | Buy | $30 → $32 |
| Jul-13-26 | Reiterated | BTIG | Buy | $16 → $17 |
| Feb-26-26 | Reiterated | Evercore ISI | $27 | |
| Feb-26-26 | Reiterated | BTIG | Buy | $19 |
| Oct-21-25 | Reiterated | Craig-Hallum | Buy | $24 → $20 |
| Oct-20-25 | Reiterated | HC Wainwright & Co. | Buy | $24 → $30 |
| Mar-07-25 | Reiterated | HC Wainwright & Co. | Buy | $22 → $24 |
| May-15-24 | Reiterated | HC Wainwright & Co. | Buy | $22 |
| May-03-13 | Downgrade | Cowen & Co. | Outperform → Underperform | |
| May-03-13 | Downgrade | Roth Capital | Buy → Sell |
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 96 | 85 | 37 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 13 | 12 | 6 | — | — | — | — | — | — | |
| Gross Profit | 83 | 73 | 31 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 47 | 44 | 30 | — | — | — | — | — | — | |
| Research and Development | 37 | 29 | 14 | — | — | — | — | — | — | |
| Other Operating Expense | 1 | 0 | -1 | — | — | — | — | — | — | |
| Operating Income | -2 | 1 | -12 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 4 | 3 | -14 | — | — | — | — | — | — | |
| Net Income Before Taxes | 1 | 4 | -26 | — | — | — | — | — | — | |
| Income Taxes | 1 | 1 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | 1 | 3 | -26 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 1 | 3 | -26 | — | — | — | — | — | — | |
| Net Income | 1 | 3 | -26 | — | — | — | — | — | — | |
| EPS (Recurring) | 0.01 | 0.08 | -0.11 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.01 | 0.08 | -0.11 | — | — | — | — | — | — | |
| EPS (Diluted) | 0.01 | 0.07 | -0.12 | — | — | — | — | — | — | |
| EBITDA | 1 | 4 | -26 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 1,611.00 | 144.29 | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 6.04 | 4.28 | 9.44 | — | — | — | — | — | — | |
| Gross Margin | 86.46 | 85.88 | 83.78 | — | — | — | — | — | — | |
| Operating Margin | -2.08 | 1.18 | -32.43 | — | — | — | — | — | — | |
| Net Margin | 1.04 | 3.53 | -70.27 | — | — | — | — | — | — | |
| Shares Outstanding | 36 | 36 | 29 | — | — | — | — | — | — | |
| Market Capitalization | 580 | 364 | 349 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Pennell Sandra | Chief Financial Officer | Mar 06 '26 | Buy | 9.04 | 5,533 | 50,018 | 77,018 | Mar 06 |
| MICHEL GERARD J | CHIEF EXECUTIVE OFFICER | Mar 02 '26 | Buy | 8.96 | 11,200 | 100,309 | 342,034 | Mar 03 |
| Sylvester John Richard | Director | Nov 21 '25 | Buy | 8.89 | 4,386 | 38,992 | 14,936 | Nov 25 |
| MICHEL GERARD J | CHIEF EXECUTIVE OFFICER | Nov 11 '25 | Buy | 8.53 | 11,500 | 98,049 | 330,834 | Nov 13 |
| Vukovic Vojo | CHIEF MEDICAL OFFICER | Jun 12 '25 | Option Exercise | 4.78 | 42,000 | 200,760 | 168,882 | Jun 13 |
| Aharon Gil | Director | May 05 '25 | Option Exercise | 10.00 | 400,000 | 4,000,000 | 3,413,468 | May 09 |
| SALAMON STEVEN A J | Director | May 05 '25 | Option Exercise | 10.00 | 400,000 | 4,000,000 | 3,413,468 | May 09 |
| Rosalind Advisors, Inc. | Director | May 05 '25 | Option Exercise | 10.00 | 400,000 | 4,000,000 | 3,413,468 | May 09 |
| SALAMON STEVEN A J | Director | Dec 24 '24 | Option Exercise | 0.01 | 603,954 | 6,040 | 1,323,919 | Dec 27 |
| Aharon Gil | Director | Dec 24 '24 | Option Exercise | 0.01 | 603,954 | 6,040 | 1,323,919 | Dec 26 |
| Rosalind Advisors, Inc. | Director | Dec 24 '24 | Option Exercise | 0.01 | 603,954 | 6,040 | 1,323,919 | Dec 26 |
| Aharon Gil | Director | Oct 30 '24 | Option Exercise | 1000.00 | 500 | 500,000 | 0 | Nov 01 |
| SALAMON STEVEN A J | Director | Oct 30 '24 | Option Exercise | 1000.00 | 500 | 500,000 | 0 | Nov 01 |
| Rosalind Advisors, Inc. | Director | Oct 30 '24 | Option Exercise | 1000.00 | 500 | 500,000 | 0 | Nov 01 |
| MICHEL GERARD J | CHIEF EXECUTIVE OFFICER | Oct 22 '24 | Option Exercise | 6.00 | 16,666 | 99,996 | 319,334 | Oct 23 |